Astex Pharmaceuticals Presents SGI-110 AML Data at ECC 2013
September 30, 2013 at 06:06 AM EDT
Astex Pharmaceuticals (NASDAQ: ASTX ) today announced that detailed clinical responses and biomarkers data of relapsed/refractory AML (r/r AML) patients treated in the Phase 1 part of the SGI-110-01 study were presented at the European Cancer Congress (ECC: ECCO-ESMO-ESTRO) in Amsterdam, Netherlands. The data were presented in the Oral Papers
